Page 18 - Lupin

Trading calls by Ajit Mishra of Religare Broking: Buy Britannia, Lupin

Britannia has been trading in a broader consolidation range of Rs 3,350-3,840 for the last one year and is currently hovering in the middle

Stocks to watch: ICICI Bank, Dish TV, Adani Ports, Jubilant Pharmova, Lupin

Dr Reddy's Laboratories (DRL) on Tuesday said it has been asked to pay $46.25 million to Australia-based Hatchtech Pty Ltd as part of an asset purchase agreement between the two parties in 2015

Lupin dips 5% on USFDA warning letter for Somerset manufacturing unit

Lupin said the company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility

Lupin gets warning letter from US health regulator for Somerset facility

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility, it said

Stocks to watch: M&M, PNB, Bharat Forge, Lupin, rate sensitive stocks

ABB Power Products on Thursday said it has resumed operations at its manufacturing facility in Bengaluru from May 28

Lupin to enter digital healthcare space; to provide platform for doctors

Lupin said it will enter the digital healthcare space in India with a focus to provide a digital therapeutics platform for doctors and patients.

This Rakesh Jhunjhunwala-owned pharma stock hits over 4-year high

Lupin rose 4 per cent to Rs 1,258.70 on the BSE in intra-day trade on Wednesday, a level that was last seen in May 2017

Lupin shares slide 4% amid profit booking post March quarter results

During the past six trading days, Lupin outperformed the market and surged 15 per cent as compared to a per cent rise in the S&P BSE Sensex till Wednesday

Lupin willing to take partners to bring mRNA Covid-19 vaccines to India

Executive says company is looking for tie-ups to bring in drugs like Remdesivir

Lupin Q4 net profit up 18% at Rs 460 cr; FY21 profit at Rs 1,216 cr

Drug maker Lupin on Thursday reported an 18 per cent increase in its consolidated net profit at Rs 460 crore for the fourth quarter, driven by robust sales across domestic and international markets

Lupin soars 8%, hits over three-year high on heavy volumes

The stock surpassed its previous high of Rs 1,121.85 touched on September 2020 and was trading at the highest level since July 2017

Stocks to watch: Nestle India, Hero Moto, ICICI Securities, Cyient, Lupin

Cyient, Tata Elxsi and 10 other companies will release their quarterly earnings on April 22

Titan, Lupin: How to trade dark horses in Rakesh Jhunjhunwala's portfolio

Titan Company needs to decisively cross and sustain above Rs 1,500 levels, supported by volume, to attract the interest of market participants

Lupin plans expansion, aims to enter Chinese market in the next one year

The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive

Regulatory clearances, US growth near term triggers for Lupin

India business has seen steady uptick growth over the last few quarters

F&O Expiry: Sensex sinks 536 pts; broader mkts outperform; bank stocks up

In the broader market, the S&P BSE MidCap index ended 0.4 per cen lower while the smallcap counterpart closed down 0.45 per cent.

Lupin, Reliance Industries: Stock picks by Ajit Mishra of Religare Broking

We're seeing consistent buying interest in the pharma pack and Lupin is also catching up with the other pharma majors

New product launches to drive growth for Lupin, US business a key trigger

This should reverse the US underperformance in FY15-20 with margins too moving up sharply

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Pharma, healthcare growing, but they face challenges beyond Covid-19

These sectors will face another tough year after coronavirus pandemic, the first challenge being vaccination of India's 1.3 billion people. Devangshu Datta explains the opportunities and threats